Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The Retatrutide for People with Type 2 Diabetes Phase 2 study was designed to look at the efficacy and safety of retatrutide for the treatment of T2D over 36 weeks
The most common baseline comorbidities were hypertension (94.6%) and hypercholesterolemia (88.9%), and common cardiovascular comorbidities included coronary heart disease (43.8%) and congestive heart failure (CHF
and (ii) the indiscriminate substitution of industrialized products already available and approved by ANVISA
In the definitive SURMOUNT-5 head-to-head trial (NEJM 2025), tirzepatide produced ~20% weight loss vs
Metformin is widely considered the first go-to diabetes medication
US$ 28.50
US$ 23.44
US$ 29.36
US$ 28.45
